Esperion Therapeutics | ESPR - Sales Revenues

Stock Price
2.07
Daily Change
0.02 0.98%
Monthly
-23.05%
Yearly
114.75%
Q2 Forecast
2.11

Esperion Therapeutics reported $168.45M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amarin USD 49.22M 451K Dec/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Cipla INR 75.18B 710M Dec/2025
CSL USD 8.33B 4.79B Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Geron USD 48.02M 820K Dec/2025
Grifols EUR 2.34B 33.3M Mar/2026
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 678M 342M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024